Targeted Therapy For RET-Rearranged Non-Small Cell Lung Cancer: Clinical Development And Future Directions

Approximately 1–2% of unselected patients with Non-small Cell Lung Cancer (NSCLC) harbor RET rearrangements resulting in enhanced cell survival and proliferation. The initial treatment strategy for RET rearranged NSCLC has been multi-target tyrosine kinase inhibition. With overall response rates (OR...

Descripción completa

Detalles Bibliográficos
Autores principales: Ackermann, Christoph Jakob, Stock, Gustavo, Tay, Rebecca, Dawod, Mohammed, Gomes, Fabio, Califano, Raffaele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767757/
https://www.ncbi.nlm.nih.gov/pubmed/31576143
http://dx.doi.org/10.2147/OTT.S171665

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767757/
https://www.ncbi.nlm.nih.gov/pubmed/31576143
http://dx.doi.org/10.2147/OTT.S171665

Ejemplares similares